diff --git a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx index e7a1de21a..f8315d7e3 100644 --- a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx +++ b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx @@ -304,11 +304,12 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = { '02042025': { priorityNews: [ - Happy New Year! As of January X, 2025, 15 level 1, 12 level 2, 18 level - 3 and 11 level 4 treatments for unique biomarker-selected indications - were added to OncoKB. A table summarizing these changes can be found{' '} + Happy New Year! As of January X, 2025, fifteen Level 1, twelve Level 2, + eighteen Level 3 and eleven Level 4 treatments for unique + biomarker-selected indications were added to OncoKB. A table summarizing + these changes can be found here{' '} here. The - Precision Oncology: 2024 in review article can be found{' '} + “Precision Oncology: 2024 in Review” article can be found{' '} - + , ], [ @@ -409,7 +410,8 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = { , 'Colorectal Cancer',
-
Sensitivity Adagrasib + Cetuximab (Level 1)
+
Sensitivity
+
Adagrasib + Cetuximab (Level 1)

Adagrasib + Panitumumab, Sotorasib + Cetuximab, Sotorasib + @@ -418,9 +420,9 @@ export const NEWS_BY_DATE: { [date: string]: NewsData } = {
Binimetinib, Cobimetinib, Trametinib (Level 4)

+
Resistance
- Resistance Cetuximab, Panitumumab, Tucatinib + Trastuzumab - (Level R1) + Cetuximab, Panitumumab, Tucatinib + Trastuzumab (Level R1)
, 'Sotorasib + Panitumumab (Level 1)',